Safety and efficacy of transbronchial radiofrequency ablation for stage IA peripheral lung cancer: a retrospective cohort study.

IF 3.5 2区医学 Q2 ONCOLOGY

Translational lung cancer research Pub Date : 2025-07-31 Epub Date: 2025-07-28 DOI:10.21037/tlcr-2025-486

Siyuan Hong, Lin Ye, Junxiang Chen, Fangfang Xie, Chuanjia Gu, Du Xu, George Cheng, Jiayuan Sun

{"title":"Safety and efficacy of transbronchial radiofrequency ablation for stage IA peripheral lung cancer: a retrospective cohort study.","authors":"Siyuan Hong, Lin Ye, Junxiang Chen, Fangfang Xie, Chuanjia Gu, Du Xu, George Cheng, Jiayuan Sun","doi":"10.21037/tlcr-2025-486","DOIUrl":null,"url":null,"abstract":"Background: Percutaneous radiofrequency ablation (RFA) is a commonly used treatment for inoperable early-stage lung cancer, though it carries a significant risk of complications. Transbronchial RFA has emerged as a promising alternative, but robust clinical evidence supporting its adoption remains scarce. This study aims to investigate the safety and efficacy of transbronchial RFA in treating early-stage peripheral lung cancer.Methods: This retrospective cohort study included patients with early-stage (IA) peripheral lung cancer who underwent transbronchial RFA due to inoperability or refusal of surgery from August 2020 to December 2023. All patients underwent transbronchial RFA under the guidance of X-ray or cone-beam computed tomography (CBCT). The safety endpoint included the incidence of adverse events in the month after ablation. The efficacy endpoints involved the local control progression-free survival (LPFS), as well as the factors affecting therapeutic outcomes.Results: A total of 46 patients with 51 tumors underwent 55 transbronchial RFA procedures. The mean age of patients was 67.7 years, and the mean lesion size was 16.4 mm. Adverse events and intervention-acquired adverse events were reported in 11.5% and 9.8% of participants. The local control analysis revealed 1-, 2-, and 3-year LPFS rates of 87.5%, 73.4%, and 69.8%, respectively. The efficacy predictor analysis revealed that transbronchial RFA guided by CBCT had significantly better LPFS compared to that of X-ray guidance (1- and 3-year LPFS rates: 97.2% vs. 55.4% and 79.3% vs. 36.9%, respectively).Conclusions: Transbronchial RFA for peripheral lung cancer showed a favorable safety profile. The efficacy of transbronchial RFA was also evaluated, and it was found that CBCT-guided bronchial ablation had better outcomes. Future studies will require prospective randomized controlled trials to further confirm its efficacy.","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 7","pages":"2736-2746"},"PeriodicalIF":3.5000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12337045/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational lung cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tlcr-2025-486","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Percutaneous radiofrequency ablation (RFA) is a commonly used treatment for inoperable early-stage lung cancer, though it carries a significant risk of complications. Transbronchial RFA has emerged as a promising alternative, but robust clinical evidence supporting its adoption remains scarce. This study aims to investigate the safety and efficacy of transbronchial RFA in treating early-stage peripheral lung cancer.

Methods: This retrospective cohort study included patients with early-stage (IA) peripheral lung cancer who underwent transbronchial RFA due to inoperability or refusal of surgery from August 2020 to December 2023. All patients underwent transbronchial RFA under the guidance of X-ray or cone-beam computed tomography (CBCT). The safety endpoint included the incidence of adverse events in the month after ablation. The efficacy endpoints involved the local control progression-free survival (LPFS), as well as the factors affecting therapeutic outcomes.

Results: A total of 46 patients with 51 tumors underwent 55 transbronchial RFA procedures. The mean age of patients was 67.7 years, and the mean lesion size was 16.4 mm. Adverse events and intervention-acquired adverse events were reported in 11.5% and 9.8% of participants. The local control analysis revealed 1-, 2-, and 3-year LPFS rates of 87.5%, 73.4%, and 69.8%, respectively. The efficacy predictor analysis revealed that transbronchial RFA guided by CBCT had significantly better LPFS compared to that of X-ray guidance (1- and 3-year LPFS rates: 97.2% vs. 55.4% and 79.3% vs. 36.9%, respectively).

Conclusions: Transbronchial RFA for peripheral lung cancer showed a favorable safety profile. The efficacy of transbronchial RFA was also evaluated, and it was found that CBCT-guided bronchial ablation had better outcomes. Future studies will require prospective randomized controlled trials to further confirm its efficacy.

查看原文本刊更多论文

经支气管射频消融治疗IA期周围性肺癌的安全性和有效性：一项回顾性队列研究。

背景：经皮射频消融（RFA）是一种常用的治疗无法手术的早期肺癌的方法，尽管它有明显的并发症风险。经支气管射频消融已成为一种很有前景的替代方法，但支持其采用的有力临床证据仍然很少。本研究旨在探讨经支气管射频消融治疗早期周围性肺癌的安全性和有效性。方法：本回顾性队列研究纳入了2020年8月至2023年12月期间因无法手术或拒绝手术而接受经支气管RFA治疗的早期（IA）周围性肺癌患者。所有患者均在x线或锥形束计算机断层扫描（CBCT）指导下行经支气管RFA。安全性终点包括消融后一个月内不良事件的发生率。疗效终点包括局部控制无进展生存期（LPFS），以及影响治疗结果的因素。结果：共46例患者51例肿瘤行55次经支气管RFA手术。患者平均年龄67.7岁，平均病灶大小16.4 mm。不良事件和干预获得性不良事件的发生率分别为11.5%和9.8%。局部对照分析显示，1年、2年和3年LPFS率分别为87.5%、73.4%和69.8%。疗效预测分析显示，CBCT引导下经支气管RFA的LPFS明显优于x线引导（1年和3年LPFS率分别为97.2%对55.4%和79.3%对36.9%）。结论：经支气管射频消融术治疗周围性肺癌具有良好的安全性。同时对经支气管RFA的疗效进行了评价，发现cbct引导下的支气管消融术效果更好。未来的研究将需要前瞻性随机对照试验来进一步证实其疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational lung cancer research Medicine-Oncology

CiteScore

7.20

自引率

2.50%

发文量

137

期刊介绍： Translational Lung Cancer Research(TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open-access journal, which was founded in March 2012. TLCR is indexed by PubMed/PubMed Central and the Chemical Abstracts Service (CAS) Databases. It is published quarterly the first year, and published bimonthly since February 2013. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer.